Skip to main content

Heart Defect, Congenital

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Xeltis
XeltisNetherlands - Eindhoven
1 program
Xeltis Bioabsorbable Pulmonary Valved ConduitN/A1 trial
Active Trials
NCT03022708Active Not Recruiting56Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
XeltisXeltis Bioabsorbable Pulmonary Valved Conduit

Clinical Trials (1)

Total enrollment: 56 patients across 1 trials

NCT03022708XeltisXeltis Bioabsorbable Pulmonary Valved Conduit

Xeltis Bioabsorbable Pulmonary Valved Conduit Pivotal Study

Start: May 2017Est. completion: Dec 202656 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.